87 related articles for article (PubMed ID: 27864890)
1. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
[TBL] [Abstract][Full Text] [Related]
2. Bcl-xL inhibition radiosensitizes
Pesch AM; Chandler BC; Michmerhuizen AR; Carter HM; Hirsh NH; Wilder-Romans K; Liu M; Ward T; Ritter CL; Nino CA; Jungles KM; Pierce LJ; Rae JM; Speers CW
Cancer Res Commun; 2022 Jul; 2(7):679-693. PubMed ID: 36381235
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 12p Amplification in Triple-Negative/
Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Zecchin D; Moore C; Michailidis F; Horswell S; Rana S; Howell M; Downward J
EMBO Mol Med; 2020 Aug; 12(8):e11987. PubMed ID: 32672423
[TBL] [Abstract][Full Text] [Related]
6. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.
Agnello L; Tortorella S; d'Argenio A; Carbone C; Camorani S; Locatelli E; Auletta L; Sorrentino D; Fedele M; Zannetti A; Franchini MC; Cerchia L
J Exp Clin Cancer Res; 2021 Jul; 40(1):239. PubMed ID: 34294133
[TBL] [Abstract][Full Text] [Related]
7. WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer.
Ertay A; Liu H; Liu D; Peng P; Hill C; Xiong H; Hancock D; Yuan X; Przewloka MR; Coldwell M; Howell M; Skipp P; Ewing RM; Downward J; Wang Y
Cell Death Dis; 2020 Nov; 11(11):1001. PubMed ID: 33221821
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.
Si Y; Xu Y; Guan J; Chen K; Kim S; Yang ES; Zhou L; Liu XM
Eng Life Sci; 2021 Jan; 21(1-2):37-44. PubMed ID: 33531889
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in
Mintz RL; Lao YH; Chi CW; He S; Li M; Quek CH; Shao D; Chen B; Han J; Wang S; Leong KW
Bioeng Transl Med; 2020 Jan; 5(1):e10152. PubMed ID: 31989039
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
Cheung A; Chenoweth AM; Johansson A; Laddach R; Guppy N; Trendell J; Esapa B; Mavousian A; Navarro-Llinas B; Haider S; Romero-Clavijo P; Hoffmann RM; Andriollo P; Rahman KM; Jackson P; Tsoka S; Irshad S; Roxanis I; Grigoriadis A; Thurston DE; Lord CJ; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2024 May; ():. PubMed ID: 38772416
[TBL] [Abstract][Full Text] [Related]
11. Identification of CSNK1D and KLK6 as two common upregulated genes present in BRCA1 mutated triple-negative breast cancer and ovarian epithelial carcinoma.
Lakis F; Ayoub R; Faour WH; Makki M; Yassine H; Fayyad-Kazan H; Abdel Sater F
Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-14. PubMed ID: 38781585
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
13. BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer.
Lee CM; Hwang Y; Jeong JW; Kim M; Lee J; Bae SJ; Ahn SG; Fang S
Cell Death Discov; 2024 Jan; 10(1):5. PubMed ID: 38182557
[TBL] [Abstract][Full Text] [Related]
14. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.
Sartore-Bianchi A; Siena S; Tonini G; Bardelli A; Santini D
Cancer Treat Rev; 2016 Dec; 51():54-62. PubMed ID: 27865140
[TBL] [Abstract][Full Text] [Related]
15. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
16. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Van Emburgh BO; Arena S; Siravegna G; Lazzari L; Crisafulli G; Corti G; Mussolin B; Baldi F; Buscarino M; Bartolini A; Valtorta E; Vidal J; Bellosillo B; Germano G; Pietrantonio F; Ponzetti A; Albanell J; Siena S; Sartore-Bianchi A; Di Nicolantonio F; Montagut C; Bardelli A
Nat Commun; 2016 Dec; 7():13665. PubMed ID: 27929064
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
Gu G; Dustin D; Fuqua SA
Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
[TBL] [Abstract][Full Text] [Related]
18. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer.
Harbeck N; Gnant M
Lancet; 2017 Mar; 389(10074):1134-1150. PubMed ID: 27865536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
